NAD+ Test: How NAD Levels Are Measured, and What a Number Means

Under every "does it work?" page on this site sits the same unanswered question. If a supplement's proven effect is that it raises NAD+, and if raising NAD+ is a laboratory result rather than a feeling, then the obvious next move is to measure it. So: can you test your NAD+ level, what would the test actually be sampling, and what would the number mean?

The short version is that NAD+ can be measured, that the research trials do measure it, and that "your NAD+ level" is a much looser phrase than it sounds — it names at least four different measurements taken from four different places in the body, none of which comes with a validated range that tells you whether you are healthy. This page explains what each measurement is and where the honest limits are.

"Your NAD+ level" is at least four different measurements

NAD+ is a coenzyme that does its work inside cells. Every test is therefore a compromise about which cells, or which fluid around them, you are willing to sample. The 2026 systematic review of NAD+ supplementation describes exactly this split when it summarizes how human trials demonstrated target engagement: through circulating measures, meaning plasma or whole blood, or through cellular measures such as peripheral blood mononuclear cells ¹.

Plasma. The extracellular fluid, and the easiest to draw. A study that quantified the plasma NAD+ metabolome by liquid chromatography with tandem mass spectrometry in healthy people across a 20-to-87 age range found something more complicated than a single falling line: plasma NAD+, NADP+ and nicotinic acid adenine dinucleotide declined with age, while the reduced forms NADH and NADPH rose, as did nicotinamide, N-methyl-nicotinamide and the products of ADP-ribosylation — and nicotinic acid, NMN and nicotinic acid mononucleotide showed no statistically significant change across age groups ². That is one blood draw producing a dozen numbers moving in different directions. "NAD+ level" is a summary of a metabolome, and which member of the metabolome a test reports changes what the result means.

Whole blood. Mostly red blood cells, and the compartment most human NMN trials report. The 12-week trial of 250 mg/day measured NAD+ and related metabolites in whole blood and found NAD+ significantly increased — while blood NMN itself did not rise ³. The 60-day dose-ranging trial likewise reported blood NAD concentrations as its primary outcome ⁴. If you want a number comparable with the published trials, whole blood is the compartment they used.

Cells. Peripheral blood mononuclear cells are the closest cheap proxy for "inside a cell." An 8-week study in 11 healthy middle-aged men, open-label and single-arm, measured NAD+ in PBMCs and reported it increased over the course of supplementation ⁵. Note the design: no placebo group and no randomization, which is a limit on the conclusion, not on the assay.

Tissue. The measurement people actually mean when they say they want to know their cellular NAD+ — and it requires a biopsy. A placebo-controlled, randomized, double-blind crossover trial supplemented 12 aged men with 1 g of nicotinamide riboside per day for 21 days and took skeletal muscle samples. Targeted metabolomics showed the muscle NAD+ metabolome was elevated. Mitochondrial bioenergetics were not altered ⁶. That single result is the most important thing on this page: the precursor reached the tissue, the tissue's NAD+ metabolome moved, and the function the NAD+ was supposed to improve did not.

Why measuring it is harder than it sounds

NAD+ is not a stable analyte you can leave in a tube. A methodological review of NAD+ quantification puts the problem plainly: most pyridine nucleotides auto-oxidize and have differing chemical stability across biological matrices, which makes accurate assessment of their concentrations an analytical challenge. The same review is blunt about the cheap options — specialized HPLC with ultraviolet detection, NMR, capillary zone electrophoresis and colorimetric enzymatic assays are inexpensive and available in most laboratories, but lack the specificity and sensitivity required to quantify human biological samples. Liquid chromatography mass spectrometry is the alternative, and only after careful attention to extraction, internal standards, analyte stability and the assay itself ⁷.

That has a direct consumer consequence. A test's price tells you nothing about whether it used a method the literature considers adequate, and "enzymatic assay" and "LC-MS" are not interchangeable words on a results page.

Sample handling is the other half of the problem. A 2023 method paper developed a dried-blood-spot approach precisely because, in its authors' words, NAD+ and its precursors are unstable in blood and difficult to measure. On their chosen card, NAD+ stability held at 85% or more for at least two weeks at 4 °C and one week at room temperature, from as little as 5 µL of blood, with calibration linear from 0.25 to 200 µM ⁸. Two things are worth carrying away. First, stability is measured in days, so how a sample traveled matters. Second, that paper says its method "has the potential to become the gold standard" — which is a plain admission that the field does not yet have one. Its authors were employees of a nutraceutical business division and an affiliated supplement company ⁸, a disclosure worth holding in mind whenever the same industry sells both the supplement and the reason to measure.

Faster methods are being built. A bioluminescent sensor protein that shifts its emitted light from blue to red on binding NAD+ has been demonstrated for rapid quantification in cell culture, tissue and blood, including in paper-based assays read with a digital camera, with results that agreed with standard testing methods ⁹. That is a real advance in convenience. It does not change anything below.

What no NAD+ test can tell you

Here is the part that matters most, and it is the reason this page is an explainer rather than a shopping guide.

There is no validated reference range that maps a number to your health. Not "the range is wide" — there is no established target. A 2023 review in Endocrine Reviews devoted to what is and is not known about NAD+ in aging biology states that NAD+ levels decrease throughout life and that the age-related decline in NAD+ bioavailability has been postulated to contribute to age-related disease, and concludes that the clinical pharmacology, metabolism and therapeutic mechanisms of NAD+ precursors remain incompletely understood ¹⁰. Postulated is doing real work in that sentence. The muscle-biopsy trial made the same point about the underlying premise from the other direction: the decline with aging has been reported in preclinical models, and human data are sparse ⁶.

A confirmed rise is not a health outcome. This is where the measurement question collapses back into the evidence question. In the trials, NAD+ went up and the outcomes frequently did not. A 2025 systematic review and meta-analysis found NMN had no significant effect on skeletal muscle index, handgrip strength, gait speed or the five-time chair-stand test in adults with a mean age over 60 ¹¹. A 2024 meta-analysis of eight randomized trials found no significant benefit on fasting glucose, fasting insulin, glycated hemoglobin, HOMA-IR or lipid profile ¹². The 2026 systematic review summarized 33 human intervention studies as showing consistent biochemical target engagement alongside functional and metabolic effects that were heterogeneous and often null ¹. So even a test that correctly shows your NAD+ rose has told you that the supplement was absorbed — the same thing the trials already established — and nothing about whether you are better off.

A single number has nothing to compare itself to. Because the compartments differ, the assays differ and the stability is time-sensitive, a result from one test is not interchangeable with a result from another. The only comparison with any footing is a before-and-after using the same sample type, the same laboratory and the same method — and even then, what you have learned is that a concentration changed.

Where you would get one

NAD+ measurement in the studies above happened in research laboratories, and it is not part of a standard clinical blood panel. To check that rather than assume it, we searched Labcorp's own provider test menu on 2026-08-30 for "nicotinamide adenine dinucleotide." It returned a single test: Vitamin B3 (Niacin and Metabolite), number 070115, serum or plasma — which measures niacin, not NAD+. In the same pass, a control search for "vitamin B12" returned Vitamin B12 (001503) plus roughly a dozen related panels, so the search was working. That is a statement about one reference lab's published menu on one date, not about every laboratory in the country, and it is worth re-checking rather than trusting indefinitely.

What is left is direct-to-consumer testing, sold outside the standard panel and usually by companies with a stake in the answer.

On price, we are going to disappoint you deliberately. We could not source current prices for consumer NAD+ tests from sellers' own pages to the standard this site holds itself to, so we are not publishing a range. A "tests typically run somewhere between X and Y" written from memory is exactly the sort of number this site exists to avoid — unverifiable, quick to age, and indistinguishable from a guess. If you are pricing one, read the seller's own checkout page on the day you buy. The same discipline is why our NAD+ IV cost page shows its work.

If you test anyway

Testing is not unreasonable — it is the only way to convert a mechanism story into a number about you. It is just important to know what you are buying: evidence that a supplement was absorbed, not evidence that it helped.

If you do it, the version with the most information in it is a paired measurement — one before you start and one after, from the same laboratory, the same sample type and the same method, taken under conditions you kept as similar as you could. A rise tells you the product was real and absorbed, which is a genuine answer to the purity question we treat as the main differentiator in the best NMN supplements, rated by evidence. It does not tell you the supplement is working, because in the trials those two things came apart.

Bottom line

One company has built a business on the loop this page describes — selling the test, defining the range it scores you against, and selling the supplement that moves you into it. We take that arrangement apart in our Jinfiniti review.

NAD+ can be measured, in plasma, in whole blood, in blood cells or in a tissue biopsy, and those are four different numbers rather than one ¹²⁵⁶. The measurement is analytically demanding, the molecule is unstable enough that sample handling matters, and the cheap assay formats are described in the methods literature as lacking the specificity and sensitivity needed for human samples ⁷⁸. Most importantly, no validated reference range links a level to an outcome: the age-related decline is described in the reviews as postulated rather than settled, human data are sparse, and in the trials NAD+ rose while muscle, function, glucose and lipid outcomes did not ^6101112. Measure if you want to know whether a product was absorbed. Do not expect a number that tells you how healthy you are. For what the supplements do and do not deliver, start with does NMN actually work?, NMN vs NR and our pillar guide to the NAD+ evidence; the trials behind all of it are indexed on our research page.

This is consumer education, not medical advice, and it is not a diagnostic recommendation. Talk to a clinician about any test you are considering and about interpreting its result.